News
XLO
1.240
-1.59%
-0.020
Weekly Report: what happened at XLO last week (0429-0503)?
Weekly Report · 2d ago
Weekly Report: what happened at XLO last week (0422-0426)?
Weekly Report · 04/29 09:27
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
NASDAQ · 04/26 14:24
Weekly Report: what happened at XLO last week (0415-0419)?
Weekly Report · 04/22 09:25
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
NASDAQ · 04/16 13:14
XILIO THERAPEUTICS INC - CURRENTLY MAY OFFER AND SELL SHARES OF CO'S COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF UP TO $18.7 MLN
Reuters · 04/15 13:03
Weekly Report: what happened at XLO last week (0408-0412)?
Weekly Report · 04/15 09:23
12 Health Care Stocks Moving In Tuesday's After-Market Session
Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. ATyr Pharma shares rose 10.45% and Corvus Pharma shares increased by 7.36%. Apyx Medical shares declined by 6.1% during the session.
Benzinga · 04/09 20:31
Weekly Report: what happened at XLO last week (0401-0405)?
Weekly Report · 04/08 09:25
Xilio Therapeutics 13G/Amended Filing Shows Rock Springs Capital Management LP Reported A 8.71% Stake In The Co As Of March 27, 2024
Benzinga · 04/05 20:41
Xilio Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 19.9% Stake In The Co As Of March 27, 2024
Benzinga · 04/05 20:40
GILEAD SCIENCES, INC REPORTS 19.9% PASSIVE STAKE IN XILIO THERAPEUTICS AS OF MARCH 27 - SEC FILING
Reuters · 04/05 20:35
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Werewolf Therapeutics, Inc. Develops modified cytokines for cancer treatment. The company is reporting data from its clinical trials of WTX-124, a modified IL-2. The drug has potential to treat cancer. A major competitor readout is near, and HOWL is a Buy instead of a Strong Buy.
Seeking Alpha · 04/04 20:57
HUT, CXAI and BDRX among pre-market losers
HUT, CXAI and BDRX among pre-market losers. Acorda Therapeutics files for Chapter 11 bankruptcy. Canoo reports mixed Q4 results. Humana, Hut 8 Corp, and iBio among other companies downgraded. Bitcoin production slips.
Seeking Alpha · 04/02 12:37
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023
Xilio Therapeutics reported earnings per share of -64 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -74 cents. Xilio reported results for the last quarter of 2013.
Investorplace · 04/02 02:53
Xilio Therapeutics reports Q4 results
Xilio Therapeutics reports Q4 results. Q4 net loss was $17.7 million, compared to $22.5 million for the quarter ended December 31, 2022. Cash and cash equivalents were $44.8 million as of March 31, 2024.
Seeking Alpha · 04/01 20:54
*Xilio Therapeutics 4Q Loss/Shr 64c >XLO
Dow Jones · 04/01 20:13
XILIO THERAPEUTICS INC - GRANTED GILEAD EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE XTX301, A TUMOR-ACTIVATED IL-12
Reuters · 04/01 20:05
Press Release: Xilio Therapeutics Announces -2-
Xilio Therapeutics is a clinical-stage company discovering and developing treatments for cancer. The company's net loss was $17.7 million for the quarter ended December 31, 2023. The year-over-year decrease was primarily driven by decreases in professional and consulting fees and stock-based compensation expenses. Xilio anticipates that its cash and cash equivalents will be sufficient to fund operations into 2024.
Dow Jones · 04/01 20:05
Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4. Granted Gilead exclusive license to develop and commercialize XTX301, a tumors-activated IL-12 Anticipates cash runway into the second quarter of 2025.
Dow Jones · 04/01 20:05
More
Webull provides a variety of real-time XLO stock news. You can receive the latest news about Xilio Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About XLO
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.